Guidelines for palivizumab prophylaxis: Are they based on infant's risk of hospitalization for respiratory syncytial viral disease?

Pediatric Infectious Disease Journal

Volumn 22, Issue 11, 2003, Pages 939-942

  Elhassan, Nahed O ^a   Stevens, Timothy P ^a   Sorbero, Melony E S ^b   Dick, Andrew W ^b   Guillet, Ronnie ^a   Hall, Caroline B ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Chronologic age; Corrected age; Palivizumab; Respiratory syncytial virus; Respiratory syncytial virus hospitalization; Respiratory syncytial virus prophylaxis

Indexed keywords

PALIVIZUMAB;

CALCULATION; CHILD HOSPITALIZATION; CHRONIC LUNG DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; GESTATIONAL AGE; HIGH RISK PATIENT; HUMAN; INFANT; INFECTION PREVENTION; INTENSIVE CARE; MODEL; NEWBORN; POLICY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; RISK FACTOR; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; HOSPITALIZATION; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INTENSIVE CARE UNITS, NEONATAL; PRACTICE GUIDELINES; PRIMARY PREVENTION; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RISK ASSESSMENT;

EID: 0345708257     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000095300.31563.f7     Document Type: Review

References (11)

1. Hall CB. Respiratory syncytial virus. In: Feigin RD, Cherry JD, eds. Textbook of pediatric infectious diseases. 5th ed. Philadelphia: Saunders (in press).
2. Henderson FW, Clyde WA Jr, et al. The etiologic and epidemiologic spectrum of bronchiolitis in pediatric practice. J Pediatr 1979;95:183-90.
3. Shay DK, Holman RC. Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 1999;282:1440-6.
4. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn of the American Academy of Pediatrics. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IVIG. Pediatrics 1998;102: 1211-16.
5. Institute of Medicine Committee on Issues and Priorities for New Vaccine Development. Prospects for immunizing against respiratory syncytial virus. In: New vaccine development, establishing priorities. vol 1. Washington, DC: National Academy of Science Press, 1988:397-409.
6. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus in high-risk infants. Pediatrics 1998;102:531-7.
7. American Academy of Pediatrics. Respiratory syncytial virus. In: Pickering LK, ed. Red Book: 2003 Report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2003:523-8.
8. Shay DK, Holman RC, Roosevelt GE, Clarke MJ, Anderson LJ. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997. J Infect Dis 2001;183:16-22.
9. Joffe S, Escobar GJ, Armstrong MA, Black SB, Lieu TA. Rehospitalization for respiratory syncytial virus among premature infants. Pediatrics 1999;104:894-9.
10. Boyce TG, Mellen BG, Mitchel EF, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr 2000;137:865-70.
11. Stevens TP, Sinkin RA, Hall CB, Maniscalco WM. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier. Arch Pediatr Adolesc Med 2000;154:55-61.